La ataxia de Friedreich es una enfermedad neurodegenerativa rara que afecta a la movilidad, el habla y la coordinación, y que ...
Investing.com -- Las acciones de Voyager Therapeutics (NASDAQ: VYGR) se desplomaron un 20% después de que la compañía anunciara un cambio en su programa de terapia génica para la esclerosis lateral am ...
Siguiendo esta dieta equilibrada y estos consejos, el usuario no experimentará estos problemas de salud. Los detalles en la ...
The annual event, held Dec. 6, 2024, at the JW Marriott Tampa Water Street, raised funds for the Friedreich’s Ataxia Research ...
At this time, I'd like to welcome everyone to the Biogen fourth-quarter and full-year 2024 earnings call and business update. [Operator instructions] Today's conference is being recorded. Thank you. I ...
After getting a green light from the European Commission, Biogen’s Skyclarys is the first approved medicine for the inherited neurological disease Friedreich’s ataxia (FA) in the EU.
Biogen’s Skyclarys is on course to becoming the first approved medicine for the inherited neurological disease Friedreich’s ataxia (FA) in the EU after it was recommended by the EMA’s human ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results